Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin production and suppressing glucagon output. GLP-1 agents demonstrate promising therapeutic results in treating type